AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12569213 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training
Number of subjects: 17
Study 12569213 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 subjects)
Number of subjects: 17
Study 11712446 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin and aspirin (Group A)
Number of subjects: 29
Study 11712446 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase, heparin, and aspirin (Group B)
Number of subjects: 29
Study 11712446 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 29
Study 8634167 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg/day
Number of subjects: 26
Study 8634167 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg/day
Number of subjects: 26
Study 8634167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 1323616 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg orally five times daily for 5 days after UV exposure, starting 1 day before exposure.
Number of subjects: 24
Study 1323616 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo, administered similarly to acyclovir group.
Number of subjects: 24
Study 6361005 — intervention group
Group type: EXPERIMENTAL
Intervention: maprotiline
Number of subjects: 49
Study 6361005 — intervention group
Group type: COMPARATOR
Intervention: doxepin
Number of subjects: 49
Study 30922327 — intervention group
Group type: EXPERIMENTAL
Intervention: Codrituzumab
Number of subjects: 0
Study 28093132 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone (CRO) with standard analgesia
Number of subjects: 60
Study 28093132 — intervention group
Group type: COMPARATOR
Intervention: Standard anaesthetic procedure (Control group)
Number of subjects: 60
Study 25861682 — intervention group
Group type: EXPERIMENTAL
Intervention: Test toothbrush (TB1)
Number of subjects: 10
Study 25861682 — intervention group
Group type: COMPARATOR
Intervention: Control toothbrush (TB2)
Number of subjects: 10
Study 23806032 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbogen (5% CO2 plus 95% O2)
Number of subjects: 288
Study 23806032 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100% O2)
Number of subjects: 288
Study 21081908 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg once daily for 7 days)
Number of subjects: 204
Study 21081908 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-phosphatidylcholine (PL2200, 325 mg once daily for 7 days)
Number of subjects: 204
Study 19951570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial integrated therapy targeting hyperglycemia, hypertension, dyslipidemia, and aspirin
Number of subjects: 150
Study 19951570 — intervention group
Group type: COMPARATOR
Intervention: Conventional outpatient treatment
Number of subjects: 150
Study 17289766 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg once daily for 7 days
Number of subjects: 119
Study 17289766 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 250 mg twice daily for 7 days
Number of subjects: 119
Study 15370020 — intervention group
Group type: EXPERIMENTAL
Intervention: Start Over and Survive (SOS) intervention
Number of subjects: 25
Study 15370020 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 25
Study 16351363 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype threat manipulation
Number of subjects: 0
Study 16351363 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 9828271 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg intravenous glucagon
Number of subjects: 10
Study 9828271 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg intravenous glucagon
Number of subjects: 10
Study 9828271 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intravenous glucagon
Number of subjects: 10
Study 9828271 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg and 0.5 mg intravenous glucagon
Number of subjects: 10
Study 9828271 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg and 1 mg intravenous glucagon
Number of subjects: 10
Study 7569009 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus radiation (n = 13)
Number of subjects: 23
Study 7569009 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone (n = 10)
Number of subjects: 23
Study 1658875 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopic porcine insulin (proinsulin less than 10 ppm)
Number of subjects: 28
Study 1658875 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin (proinsulin less than 1 ppm)
Number of subjects: 28
Study 1658875 — intervention group
Group type: COMPARATOR
Intervention: Bovine insulin (proinsulin less than 3,000 ppm)
Number of subjects: 28
Study 7148360 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide given before anaesthesia
Number of subjects: 58
Study 7148360 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study 30593882 — intervention group
Group type: EXPERIMENTAL
Intervention: Chat-based instant messaging support combined with brief interventions for smoking cessation
Number of subjects: 1172
Study 30593882 — intervention group
Group type: COMPARATOR
Intervention: Brief advice to quit plus a self-help booklet at baseline
Number of subjects: 1172
Study 28117264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle balance taping (ABT) with kinesiology tape
Number of subjects: 15
Study 28117264 — intervention group
Group type: COMPARATOR
Intervention: Placebo taping
Number of subjects: 15
Study 28117264 — intervention group
Group type: COMPARATOR
Intervention: No taping
Number of subjects: 15
Study 26849270 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzene exposure
Number of subjects: 317
Study 26849270 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exposed)
Number of subjects: 317
Study 25456420 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamisoyo-San multi-compound extract
Number of subjects: 147
Study 25456420 — intervention group
Group type: COMPARATOR
Intervention: Gamisoyo-San individual extract mixture
Number of subjects: 147
Study 25456420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 21920532 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 59
Study 19170780 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile film unit
Number of subjects: 499
Study 19170780 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile digital unit
Number of subjects: 499
Study 19170780 — intervention group
Group type: COMPARATOR
Intervention: Stationary unit
Number of subjects: 499
Study 17254923 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical score based on estimated blood loss, lowest heart rate, and lowest mean arterial pressure
Number of subjects: 1070
Study 16321601 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinegar
Number of subjects: 11
Study 16321601 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut products
Number of subjects: 11
Study 16321601 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 11
Study 11932288 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg.d rhIGF-I/IGFBP-3
Number of subjects: 30
Study 11932288 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg.d rhIGF-I/IGFBP-3
Number of subjects: 30
Study 11932288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9871948 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR) group, with 5 hours in bed
Number of subjects: 16
Study 9871948 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL) group, with 11 hours in bed
Number of subjects: 16
Study 8537870 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sanguinarium (ABDS-S)
Number of subjects: 17
Study 8537870 — intervention group
Group type: COMPARATOR
Intervention: Control (oral hygiene quadrant)
Number of subjects: 17
Study 31292267 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT (Radiochemotherapy)
Number of subjects: 369
Study 31292267 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT + RHT (Radiochemotherapy + Regional Hyperthermia)
Number of subjects: 369
Study 31292267 — intervention group
Group type: COMPARATOR
Intervention: RT (Radiotherapy)
Number of subjects: 369
Study 31292267 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT
Number of subjects: 369
Study 31292267 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 369
Study 31292267 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT + RHT
Number of subjects: 369
Study 31292267 — intervention group
Group type: COMPARATOR
Intervention: RCT + RHT vs RCT
Number of subjects: 369
Study 29355162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 0.25 mg/kg dexamethasone in 5 ml solution
Number of subjects: 94
Study 29355162 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline (control)
Number of subjects: 94
Study 25615272 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-min language samples
Number of subjects: 60
Study 25615272 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min language samples
Number of subjects: 60
Study 25615272 — intervention group
Group type: COMPARATOR
Intervention: 1-min and 3-min language samples
Number of subjects: 60
Study 25615272 — intervention group
Group type: COMPARATOR
Intervention: 22-min language samples
Number of subjects: 60
Study 23591400 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan, cisplatin, and bevacizumab
Number of subjects: 27
Study 21284406 — intervention group
Group type: EXPERIMENTAL
Intervention: palonosetron 0.5 μg/kg
Number of subjects: 150
Study 21284406 — intervention group
Group type: EXPERIMENTAL
Intervention: palonosetron 1.0 μg/kg
Number of subjects: 150
Study 21284406 — intervention group
Group type: EXPERIMENTAL
Intervention: palonosetron 1.5 μg/kg
Number of subjects: 150
Study 17034926 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic matrix and wooden wedge
Number of subjects: 23
Study 17034926 — intervention group
Group type: COMPARATOR
Intervention: Polyester matrix and reflective wedge
Number of subjects: 23
Study 16234576 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel wound dressing containing a combination of endopeptidases
Number of subjects: 10
Study 12704989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy and physical preventive therapy
Number of subjects: 50
Study 12704989 — intervention group
Group type: COMPARATOR
Intervention: Clinical follow-up only
Number of subjects: 50
Study 12704989 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy
Number of subjects: 50
Study 12704989 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical operation of lymphatic-venous anastomoses
Number of subjects: 50
Study 10070130 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine infusion [0.4 mg/m2 bolus, 0.4 mg. (m2)‐1. h‐1] for 2 h
Number of subjects: 12
Study 10070130 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 12
Study 10070130 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine infusion
Number of subjects: 12
Study 7737228 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (0.1 mg.kg‐1 h‐1, n = 32)
Number of subjects: 66
Study 7737228 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (1 microgram.kg‐1 min‐1, n = 34)
Number of subjects: 66
Study 2344229 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg capsules t.i.d.
Number of subjects: 27
Study 2344229 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg capsules t.i.d.
Number of subjects: 27
Study 7329736 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 trials of continuous reinforcement
Number of subjects: 40
Study 7329736 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 trials of 25% partial reinforcement
Number of subjects: 40
Study 7329736 — intervention group
Group type: COMPARATOR
Intervention: Traditional noninformed extinction (informed half)
Number of subjects: 40
Study 7329736 — intervention group
Group type: COMPARATOR
Intervention: Informed extinction (thermal stimulator removed)
Number of subjects: 40
Study 30169738 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal subdural drain
Number of subjects: 577
Study 30169738 — intervention group
Group type: COMPARATOR
Intervention: Parietal subdural drain
Number of subjects: 577
Study 30169738 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdural drain
Number of subjects: 577
Study 30169738 — intervention group
Group type: COMPARATOR
Intervention: Subgaleal drain
Number of subjects: 577
Study 30169738 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative drainage for 1 day
Number of subjects: 577
Study 30169738 — intervention group
Group type: COMPARATOR
Intervention: Postoperative drainage for 2 days
Number of subjects: 577
Study 29020189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150 μg/kg) administered every 3 months for 3 years
Number of subjects: 0
Study 29020189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150 μg/kg) administered annually for 3 years
Number of subjects: 0
Study 25720986 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-piece implants
Number of subjects: 60
Study 25720986 — intervention group
Group type: EXPERIMENTAL
Intervention: One-piece implants
Number of subjects: 60
Study 24361312 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness exercise (body scan)
Number of subjects: 110
Study 24361312 — intervention group
Group type: COMPARATOR
Intervention: Control (audio book)
Number of subjects: 110
Study 23271901 — intervention group
Group type: EXPERIMENTAL
Intervention: OT group (trained obesity group)
Number of subjects: 70
Study 23271901 — intervention group
Group type: COMPARATOR
Intervention: AWT group (trained appropriate weight group)
Number of subjects: 70
Study 23271901 — intervention group
Group type: COMPARATOR
Intervention: OWT group (trained overweight group)
Number of subjects: 70
Study 23271901 — intervention group
Group type: EXPERIMENTAL
Intervention: All trained groups (AWT, OWT, OT)
Number of subjects: 70
Study 23271901 — intervention group
Group type: COMPARATOR
Intervention: C groups (AWC, OWC, OC)
Number of subjects: 70
Study 19827649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipantil 200M (phenofibrate) 200 mg for 12 weeks
Number of subjects: 26
Study 17396620 — intervention group
Group type: EXPERIMENTAL
Intervention: Emilok (test formulation)
Number of subjects: 36
Study 17396620 — intervention group
Group type: COMPARATOR
Intervention: Commercially available original preparation (reference formulation)
Number of subjects: 36
Study 16285942 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment (omeprazole plus amoxicillin for 5 days, followed by omeprazole plus clarithromycin plus tinidazole for another 5 days)
Number of subjects: 78
Study 16285942 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (omeprazole, amoxicillin, and metronidazole for 1 week)
Number of subjects: 78
Study 12045680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention plus standard HIV test counseling
Number of subjects: 248
Study 12045680 — intervention group
Group type: COMPARATOR
Intervention: Standard HIV test counseling
Number of subjects: 248
Study 9564988 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg orally once daily for 10 to 14 days
Number of subjects: 329
Study 9564988 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 329
Study 8770707 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPEX)
Number of subjects: 6
Study 8770707 — intervention group
Group type: COMPARATOR
Intervention: Control group (immunosuppressive drug regimen without TPEX)
Number of subjects: 6
Study 1978473 — intervention group
Group type: EXPERIMENTAL
Intervention: remoxipride (75‐375 mg daily)
Number of subjects: 61
Study 1978473 — intervention group
Group type: COMPARATOR
Intervention: thioridazine (150‐750 mg daily)
Number of subjects: 61
Study 365205 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylates (3.9 g per day)
Number of subjects: 195
Study 365205 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathy
Number of subjects: 195
Study 365205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 30146682 — intervention group
Group type: EXPERIMENTAL
Intervention: NHSDP (NGO Health Services Delivery Project)
Number of subjects: 810
Study 30146682 — intervention group
Group type: EXPERIMENTAL
Intervention: MOHFW (Ministry of Health and Family Welfare)
Number of subjects: 810
Study 30146682 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall responsiveness
Number of subjects: 810
Study 30146682 — intervention group
Group type: EXPERIMENTAL
Intervention: Domains of responsiveness
Number of subjects: 810
Study 30146682 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations
Number of subjects: 810
Study 29482107 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeCare intervention
Number of subjects: 294
Study 29482107 — intervention group
Group type: COMPARATOR
Intervention: Child welfare services as usual
Number of subjects: 294
Study 26843390 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 40
Study 24595630 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg daily
Number of subjects: 40
Study 22088831 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 8844
Study 22088831 — intervention group
Group type: COMPARATOR
Intervention: CT colonography
Number of subjects: 8844
Study 19514558 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine
Number of subjects: 360
Study 19514558 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg terazosin
Number of subjects: 360
Study 19514558 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine plus 2 mg terazosin
Number of subjects: 360
Study 17430981 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 18
Study 17430981 — intervention group
Group type: EXPERIMENTAL
Intervention: Off stimulation condition
Number of subjects: 18
Study 17430981 — intervention group
Group type: EXPERIMENTAL
Intervention: On stimulation condition
Number of subjects: 18
Study 17430981 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study 15625213 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 34
Study 15625213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12198056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 micrograms plus magnesium sulfate 50 mg
Number of subjects: 52
Study 12198056 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal fentanyl 25 micrograms plus saline
Number of subjects: 52
Study 10426640 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Joel-Cohen technique
Number of subjects: 72
Study 10426640 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel technique
Number of subjects: 72
Study 8524989 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 27
Study 8524989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8524989 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 27
Study 2181788 — intervention group
Group type: EXPERIMENTAL
Intervention: telenzepine 3 mg nocte
Number of subjects: 163
Study 2181788 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 300 mg nocte
Number of subjects: 163
Study 6769448 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram 2 mg ml‐1
Number of subjects: 53
Study 6769448 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose alone
Number of subjects: 53
Study 31995812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine treatment
Number of subjects: 28
Study 31995812 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study 31995812 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline GBC
Number of subjects: 28
Study 31995812 — intervention group
Group type: EXPERIMENTAL
Intervention: GBC preprocessing with GSR
Number of subjects: 28
Study 29047145 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific opioid dosing protocol
Number of subjects: 52
Study 29047145 — intervention group
Group type: COMPARATOR
Intervention: Weight-based opioid dosing protocol
Number of subjects: 52
Study 27496180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy added to treatment as usual
Number of subjects: 487
Study 27496180 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 487
Study 24138344 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccalized occlusion (BO)
Number of subjects: 15
Study 24138344 — intervention group
Group type: COMPARATOR
Intervention: Fully bilateral balanced occlusion (BBO)
Number of subjects: 15
Study 24138344 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingualized occlusion
Number of subjects: 15
Study 23427393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Xuebijing plus conventional therapy (Group B)
Number of subjects: 36
Study 23427393 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Group A)
Number of subjects: 36
Study 23427393 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 36
Study 21078806 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐FP‐CIT
Number of subjects: 16
Study 21078806 — intervention group
Group type: COMPARATOR
Intervention: Citalopram infusion (blocking SERT)
Number of subjects: 16
Study 21078806 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐PE2I
Number of subjects: 16
Study 18818895 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar total disc replacement
Number of subjects: 3180
Study 15806416 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (100 mg/day)
Number of subjects: 62
Study 15806416 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (32.40+/‐2.8 mg/day)
Number of subjects: 62
Study 15806416 — intervention group
Group type: COMPARATOR
Intervention: Both Methadone and Buprenorphine
Number of subjects: 62
Study 12821550 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement with CMR in patients with CAD (27 patients)
Number of subjects: 90